Malignant Phonic Tics

  • Joseph JankovicEmail author
Part of the Current Clinical Neurology book series (CCNEU)


Phonic tics are typically associated with motor tics and the combination usually suggests the diagnosis of Tourette syndrome. Although phonic tics are often mild, in some cases they may be severe and disabling. In addition to causing vocal cord and throat irritation, coprolalia can be socially isolating and lead to adversarial and even legal difficulties for the affected individual. When such “malignant phonic tics” fail to improve with anti-dopaminergic drugs, botulinum toxin treatment or even deep brain stimulation may be required.


Vocal Cord Tardive Dyskinesia Tourette Syndrome Tourette Syndrome Patient BoNT Injection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material (279,307 KB)


  1. 1.
    Kurlan R. Clinical practice. Tourette’s Syndrome. N Engl J Med. 2010;363(24):2332–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Jankovic J, Kurlan R. Tourette Syndrome: evolving concepts. Mov Disord. 2011;26(6):1149–56. doi: 10.1002/mds.23618. Epub 2011 Apr 11.PubMedCrossRefGoogle Scholar
  3. 3.
    Jankovic J (1997) Phenomenology and classification of tics. In: Jankovic J (ed) Tourette ­syndrome. Neurol CI N Am, vol 15. WB Saunders, Philadelphia. pp 267–275.Google Scholar
  4. 4.
    Jankovic J. Tourette’s syndrome. N Engl J Med. 2001;345:1184–92.PubMedCrossRefGoogle Scholar
  5. 5.
    Leckman J. Tourette’s syndrome. Lancet. 2002;360:1577–86.PubMedCrossRefGoogle Scholar
  6. 6.
    The Tourette Syndrome Classification Study Group. Definitions and classification of tic disorders. Arch Neurol. 1993;50:1013–6.CrossRefGoogle Scholar
  7. 7.
    Freeman RD, Zinner SH, Müller-Vahl K, et al. Coprophenomena in Tourette syndrome. Dev Med Child Neurol. 2009;51:218–27.PubMedCrossRefGoogle Scholar
  8. 8.
    Jankovic J, Kwak C, Frankoff R. Tourette syndrome and the law. J Neuropsychiatry Clin Neurosci. 2006;18:86–95.PubMedCrossRefGoogle Scholar
  9. 9.
    Krauss JK, Jankovic J. Severe motor tics causing cervical myelopathy in Tourette’s syndrome. Mov Disord. 1996;11:563–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Jankovic J, Sekula SL, Milas D. Dermatological manifestations of Tourette’s syndrome and obsessive-compulsive disorder. Arch Dermatol. 1998;134:113–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Cheung MY, Shahed J, Jankovic J. Malignant Tourette syndrome. Mov Disord. 2007;22:1743–50.PubMedCrossRefGoogle Scholar
  12. 12.
    Scott B, Jankovic J, Donovan D. Botulinum toxin into vocal cord in the treatment of malignant coprolalia associated with Tourette’s syndrome. Mov Disord. 1996;11:431–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Salloway S, Stewart C, Israeli L. Botulinum toxin for refractory vocal tics. Mov Disord. 1996;11:746–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Trimble M, Whurr R, Brookes F, Robertson M. Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections. Mov Disord. 1998;13:617–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Jeffries K, Schooler C, Schoenbach C, Herscovitch P, Chase T, Braun A. The functional neuroanatomy of Tourette’s syndrome: an FDG PET study III: functional coupling of regional cerebral metabolic rates. Neuropsychopharmacology. 2002;27:92–104.PubMedCrossRefGoogle Scholar
  16. 16.
    Albin RL, Mink JW. Recent advances in Tourette syndrome research. Trends Neurosci. 2006;29:175–82.PubMedCrossRefGoogle Scholar
  17. 17.
    Pourfar M, Feigin A, Tang CC, et al. Abnormal metabolic brain networks in Tourette ­syndrome. Neurology. 2011;76:944–52.PubMedCrossRefGoogle Scholar
  18. 18.
    Lang A. Patient perception of tics and other movement disorders. Neurology. 1991;41:223–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Kwak C, Vuong KD, Jankovic J. Premonitory sensory phenomenon in Tourette’s syndrome. Mov Disord. 2003;18:1530–3.PubMedCrossRefGoogle Scholar
  20. 20.
    Prado HS, Rosario MC, Lee J, et al. Sensory phenomena in obsessive–compulsive disorder and tic disorders: a review of the literature. CNS Spectr. 2008;13:425–32.PubMedGoogle Scholar
  21. 21.
    Kwak C, Hanna P, Jankovic J. Botulinum toxin in the treatment of tics. Arch Neurol. 2000;57:1190–3.PubMedCrossRefGoogle Scholar
  22. 22.
    Marras C, Andrews D, Sime E, Lang A. Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology. 2001;56:605–10.PubMedCrossRefGoogle Scholar
  23. 23.
    Aguirregomozcorta M, Pagonabarraga J, Diaz-Manera J, et al. Efficacy of botulinum toxin in severe Tourette syndrome with dystonic tics involving the neck. Parkinsonism Relat Disord. 2008;14:443–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Jimenez-Jimenez F, Garcia-Ruiz P. Pharmacological options for the treatment of Tourette’s disorder. Drugs. 2001;61:2207–20.PubMedCrossRefGoogle Scholar
  25. 25.
    Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol. 2009;8:844–56.PubMedCrossRefGoogle Scholar
  26. 26.
    Shprecher D, Kurlan R. The management of tics. Mov Disord. 2009;24:15–24.PubMedCrossRefGoogle Scholar
  27. 27.
    Peña MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011;26:147–52.PubMedCrossRefGoogle Scholar
  28. 28.
    Silay Y, Jankovic J. Emerging drugs in Tourette syndrome. Expert Opin Emerg Drugs. 2005;10:365–80.PubMedCrossRefGoogle Scholar
  29. 29.
    Kenney C, Hunter C, Mejia N, Jankovic J. Tetrabenazine in the treatment of Tourette ­syndrome. J Ped Neurol. 2007;5:9–13.Google Scholar
  30. 30.
    Scahill L, Chappell P, Kim Y, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158:1067–74.PubMedCrossRefGoogle Scholar
  31. 31.
    Gaffney G, Perry P, Lund B, Bever-Stille K, Arndt S, Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry. 2002;41:330–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Piacentini J, Woods DW, Scahill L, et al. Behavior therapy for children with Tourette disorder: randomized controlled trial. JAMA. 2010;303:1929–37.PubMedCrossRefGoogle Scholar
  33. 33.
    Jankovic J, Albanese A, Atassi MZ, Dolly JO, Hallett M, Mayer N. Botulinum toxin. Therapeutic clinical practice and science. Philadelphia, PA: Saunders (Elsevier); 2009. p. 1–492.Google Scholar
  34. 34.
    Ackermans L, Duits A, van der Linden C, et al. Double-blind clinical trial of thalamic stimulation in patients with Tourette syndrome. Brain. 2011;134:832–44.PubMedCrossRefGoogle Scholar
  35. 35.
    Martinez-Fernandez R, Zrinzo L, Aviles-Olmos I, et al. Deep brain stimulation for Gilles de la Tourette syndrome: a case series targeting subregions of the globus pallidus internus. Mov Disord. 2011;26(10):1922–30. doi: 10.1002/mds.23734.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of NeurologyParkinson’s Disease Center and Movement Disorders Clinic, Baylor College of MedicineHoustonUSA

Personalised recommendations